About processa pharmaceuticals inc - PCSA
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.
PCSA At a Glance
Processa Pharmaceuticals, Inc.
601 21st Street
Vero Beach, Florida 32960
| Phone | 1-772-453-2899 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -13,563,834.00 | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PCSA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.328 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.126 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PCSA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,130,319.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PCSA Liquidity
| Current Ratio | 2.536 |
| Quick Ratio | 2.536 |
| Cash Ratio | 2.476 |
PCSA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -245.658 |
| Return on Equity | -372.967 |
| Return on Total Capital | -243.197 |
| Return on Invested Capital | -372.942 |
PCSA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |